{
  "docId": "019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "docSlug": "be407bbae8f9e005c3f7268aea2b4f13",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 34 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 34,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a list of key benefits to summarize the product's market and clinical position.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2fc9-715d-b6e1-faa3fd3ed1eb/5",
  "deckHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "deckJsonHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb.json",
  "deckAnchorHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.58,
        "w": 0.44,
        "x": 0.03,
        "y": 0.275
      },
      "kind": "image",
      "text": "Hand holding a pill in a lab setting",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7aa7a157-f3fe-4063-9a0b-c048cc91147d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.54,
        "y": 0.39
      },
      "kind": "list",
      "text": "Promising efficacy signals observed from ALS Phase 2a clinical trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b9eb705-b59e-42c9-b195-1e64cd80149a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.54,
        "y": 0.78
      },
      "kind": "list",
      "text": "Expedited regulatory pathway (orphan drug designation / 505(b)2 pathway)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c812973-fdfd-4109-89ed-d5ccd24b7810",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.54,
        "y": 0.26
      },
      "kind": "list",
      "text": "Novel combination therapy designed to address multiple disease targets in a synergistic manner",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bf09256-464b-4410-a04d-df29a6d8275d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.54,
        "y": 0.52
      },
      "kind": "list",
      "text": "ALS Phase 2b top-line results from placebo-controlled clinical trial expected in Q4 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99111f5d-b862-422d-8160-c595a7c70b9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.54,
        "y": 0.65
      },
      "kind": "list",
      "text": "Patent coverage for novel formulation, method & combination (until 2038)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b281546e-4829-4a5d-9b53-277cec89be2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "PrimeC: Value Proposition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "266cc8ce-7ad5-4eed-8502-0730031971a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "a6f6d67b-e3b5-4237-8f7f-2d28ca4abd76",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem by highlighting the limitations of current treatments.",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 34,
      "from": 5,
      "beatId": "e49a51a7-5d8f-48c6-bbde-aebd1ab25027",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a potential solution to the problem of limited ALS treatment options.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "dc659062-6b4a-4152-86a1-bfaaa43636cd",
      "evidence": "The document highlights the limitations of current treatments and the need for effective therapies.",
      "position": 0,
      "objective": "What is the cost of not developing effective ALS treatments?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 34,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "c317ff20-e462-4b87-8745-365a96908ee6",
      "evidence": "The document outlines the development process and clinical trials for PrimeC.",
      "position": 1,
      "objective": "What are the key tasks that need to be done to develop PrimeC as a treatment for ALS?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.8,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}